PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
49.06
ESG score 80-90% of Biotechnology median of 57.45. Martin Whitman would look for hidden ESG liabilities and regulatory risks.
63.54
Environmental score 1.1-1.2x Biotechnology median of 54.30. Philip Fisher would examine if superior environmental practices support long-term competitive positioning.
31.02
Social score below 80% of Biotechnology median of 62.47. Michael Burry would check for potential boycott risks and regulatory compliance issues.
52.63
Governance score 90-95% of Biotechnology median of 56.90. John Neff would demand higher returns to compensate for below-average governance oversight.